Nichi-Iko Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nichi-Iko Pharmaceutical Co., Ltd.
Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
London university ready to launch clinical trials of vaccine based on self-amplifying RNA technology shortly.
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
- Generic Drugs
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Elmed Eisai Co., Ltd
- Nichi-Iko Medical Practice Institution Co., Ltd.
- Yakuhan Pharmaceutical Co., Ltd.
- Nichi-Iko Pharma Tech Co., Ltd.
- Omega Laboratories Limited
- Sagent Pharmaceuticals Inc.
- Nihon Iyakuhin Kogyo Co., Ltd.